Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary

Institute of Medicine

doi:10.17226/13237

Proceedings

VIEW LARGER COVER

Public Engagement and Clinical Trials

New Models and Disruptive Technologies: Workshop Summary

(2012)

Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.

Contributor(s): Institute of Medicine; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation; Victoria Weisfeld, Rebecca A. English, and Anne B. Claiborne, Rapporteurs

Topics

Suggested Citation

Institute of Medicine. 2012. Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary. Washington, DC: The National Academies Press. https://doi.org/10.17226/13237.

Import this citation to:

Publication Info

140 pages | 6 x 9 |

ISBNs:

Paperback: 978-0-309-21929-7
Ebook: 978-0-309-21932-7

DOI: https://doi.org/10.17226/13237

Chapters		skim
Front Matter	i-xvi
1 Introduction	1-4
2 Framing the Problem	5-16
3 Recruitment Challenges in Clinical Trials for Different Diseases and Conditions	17-30
4 Models for Public Engagement	31-38
5 Messages and Methods for Public Engagement	39-48
6 The Media	49-54
7 Novel Clinical Trial Designs	55-64
8 The Health System's Structure and Culture	65-74
9 Toward a Patient-Centered Strategy for Clinical Trials	75-84
References	85-88
Appendix A: Workshop Agenda	89-98
Appendix B: The Clinical Trials Process	99-100
Appendix C: Participant Biographies	101-124

What is skim?

The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.

Copyright Information

The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:

Republish text, tables, figures, or images in print
Post on a secure Intranet/Extranet website
Use in a PowerPoint Presentation
Distribute via CD-ROM
Photocopy

Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:

Rightslink Customer Care
Tel (toll free): 877/622-5543
Tel: 978/777-9929
E-mail: customercare@copyright.com
Web: http://www.rightslink.com

To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.

To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.

Loading stats for Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary...